Overview

Dabrafenib is a BRAF V600–selective inhibitor that directly targets the mutant BRAF kinase at the top of the MAPK cascade. In BRAF V600–mutant tumors, mutant BRAF drives continuous MEK–ERK signaling, and dabrafenib interrupts this at the entry point. The 50 mg capsule is widely specified because, in combination with a MEK inhibitor such as trametinib, it forms one of the best-established precision regimens for BRAF-driven disease and is referenced in multiple international guidelines for melanoma and thoracic oncology. Its manageable capsule formulation supports outpatient combination therapy without routine infusion visits, which simplifies long-term adherence for patients living with metastatic disease.

How It Works

Dabrafenib binds the active conformation of mutant BRAF and prevents MEK phosphorylation, cutting the proliferative signal at its source. Used alone it can paradoxically reactivate MAPK in RAS-wild-type cells, which is why guideline practice pairs it with a MEK blocker. The combination delivers more complete pathway inhibition and delays the emergence of resistance compared with monotherapy, while also improving intracranial penetration in BRAF-mutant brain metastases relative to some alternatives. Selected BRAF V600 isoforms are neutralized before they can phosphorylate MEK, and the partner MEK inhibitor then captures any residual signal, narrowing escape routes the tumor might otherwise exploit.

Indications

Dabrafenib is indicated, in combination, for BRAF V600–mutant unresectable or metastatic melanoma and for BRAF V600E–mutant non-small cell lung cancer. It also has a role in anaplastic thyroid carcinoma and in certain pediatric low-grade gliomas carrying the mutation. A confirmed BRAF V600 result guides selection, and tissue or plasma testing can both be used depending on local laboratory capability and urgency. Expanding label experience also covers adjuvant melanoma in node-positive disease, lengthening the treatment window and the corresponding supply horizon for distribution partners.

Dosage & Administration

The combination uses dabrafenib 150 mg twice daily with trametinib 2 mg daily, with strengths including 50 mg capsules enabling flexible titration. Dose holds follow managing pyrexia, skin, and cardiac signals, and febrile episodes are evaluated promptly per the management plan.

Storage & Sourcing

Capsules are supplied in sealed blister packs with cold-chain-compatible secondary packaging. GIVE LIFE TIME International issues lot-specific certificates of analysis for B2B distribution.

FAQ

Q: Why combine dabrafenib with trametinib? A: Dual BRAF plus MEK blockade avoids the MAPK rebound seen with single-agent BRAF inhibition and improves durability.

Q: Which tumors qualify for dabrafenib? A: BRAF V600–mutant melanoma, non-small cell lung cancer, anaplastic thyroid carcinoma, and select pediatric gliomas.

Q: How is combination dosing structured? A: Dabrafenib 150 mg twice daily pairs with trametinib 2 mg daily, adjusted via 50 mg capsule strengths when needed.